Erasca Reports Q3 2026 Results, $947.8 Million in Cash

Erasca reported a third-quarter 2026 net loss of $51.3 million, or $0.15 per share, and cash, cash equivalents, and marketable securities of $947.8 million as of September 30. The company received FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic cancer and outlined plans to advance…